Loading
Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer.
Joaquim Bellmunt was principal investigator of KEYNOTE-045, which showed pembrolizumab improves survival over second-line chemotherapy in platinum-refractory urothelial cancer, the first randomised survival benefit for immunotherapy in the disease. He developed the Bellmunt prognostic score and led the vinflunine and TCGA bladder subtype work. He directs the bladder cancer centre at Dana-Farber.
Shares PD-1, Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares PD-1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares Dana-Farber Brigham Cancer Center, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Dana-Farber Brigham Cancer Center, PD-1, Pembrolizumab, Immune checkpoint inhibitors.
Shares Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag urothelial.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.